一个由奥西默蒂尼布诱导的快速进展的糖尿病病病例
Kazunori Karasawa1, Ken-Ichi Akiyama1, Taro Akihisa1
1Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Case reports in nephrology and dialysis
|October 30, 2023
概括
某些癌症药物可以加速糖尿病病的进展. 像奥西默提尼布这样的受体氨酸激酶抑制剂 (RTKI) 可能会诱导脏血栓性微血管病变 (TMA),使糖尿病患者的功能恶化.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病是一种日益严重的全球健康问题,具有复杂的病理机制.
- 早期糖尿病病的高血糖损害了血管内皮细胞,增加了血管内皮生长因子 (VEGF) 的 podocytes,导致球膜缩,底层膜加厚,和介质膜增生.
- 性血栓性微血管病 (TMA) 可以在糖尿病病中发展,导致功能逐渐恶化,特别是严重的细胞损伤.
研究的目的:
- 研究受体氨酸激酶抑制剂 (RTKI) 在加速糖尿病病中的潜在作用.
- 报告与 osimertinib 治疗相关的糖尿病病迅速进展的病例.
主要方法:
- 关于糖尿病病原体和RTKI机制的文献综述.
- 一个患有糖尿病脏病和肺腺癌的患者的临床案例研究,接受了 osimertinib.
主要成果:
- 通过抑制细胞中的VEGF受体-2氨酸激酶,RTKI可能会抑制VEGF分泌.
- 这种抑制可以导致脏TMA和糖尿病脏病的快速恶化.
- 一例病例显示,在4个月内从早期的糖尿病脏病进展到末期脏病.
结论:
- 奥西默提尼布是一种表皮生长因子受体 (EGFR) -TKI,可以诱导脏TMA并加速糖尿病脏病.
- 在接受EGFR-TKI治疗的糖尿病患者中,密切监测功能至关重要.
- 了解药物诱导的毒性对于管理患有并存疾病的患者至关重要.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.7K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
600
相关概念视频
01:24Chronic Kidney Disease II: Clinical Manifestations
12
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
12
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:25Chronic Kidney Disease I: Introduction
18
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
18
01:28Chronic Kidney Disease III: Interprofessional Care
21
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
21
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:11Renal Failure: Dose Adjustments
97
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
97